The NAPOLI 3 trial: nalirifox in metastatic pancreatic cancer
During the interview, Professor Dr. Zev Wainberg from the University of California, Los Angeles, presents additional results from the phase 3 NAPOLI-3 TRIAL. The trial aimed to compare the efficacy of NALIRIFOX (liposomal irinotecan + 5-FU + LV + oxaliplatin) with Gemcitabine + nab-paclitaxel in a head-to-head comparison.
Professor Wainberg provides insightful comments on the outcome of the study, paying particular attention to the additional data presented at the conference in Barcelona. These additional data include a sensitivity analysis of survival, which sheds further light on the findings of the trial.
With the educational support of:
